Agilent Technologiesvs.Danaher
A vs DHR · both in Life science tools, part of the Medicine, pharma & life science value chain: Instruments, reagents and equipment for research, development and production.
Danaher is about 3.2× larger than Agilent Technologies by market cap; Agilent Technologies trades at the lower P/E (33.3 vs 38.5); year to date, Agilent Technologies leads (+24.3% vs −5.0%).
Side by side
| A | DHR | |
|---|---|---|
| Market cap | $48B | $154B |
| Price | $170.54 | $219.81 |
| Today | +1.4% | +1.1% |
| Return YTD | +24.3% | −5.0% |
| Return 1Y | +22.0% | +6.1% |
| Since June 26, 2026 | +25.4% | +12.0% |
| P/E | 33.3 | 38.5 |
| P/S | 6.5 | 6.1 |
| P/B | 6.5 | 2.9 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Agilent TechnologiesA
Laboratory analysis is the business: LC/MS and other analytical instruments, sold with the consumables and diagnostic reagents that keep them running.
Full A profile →DanaherDHR
Cytiva supplies the equipment biologics are made with; Cepheid runs molecular diagnostics. Danaher owns both, along with a wider set of life science instruments.
Full DHR profile →More A & DHR comparisons
Other head-to-heads in the Life science tools segment.